● Rongchang Pharmaceuticals, Ltd. was officially established.
● New hemorrhoids drug “Rongchang Gangtai” anti-hemorrhoids patch officially enter into production and launched in market. The new drug was developed under the guidance of traditional Chinese medical theories and produced with modern technologies.
● The Gangtai anti-hemorrhoids patch with optimized recipe was awarded “National New Drug Certificate” and was included in the national level traditional Chinese medicine of confidential category.
● The CFDA(China Food and Drug Administration) authorized new drug “Sweet Dream Oral Liquid” officially enter into production and was included in the national level traditional Chinese medicine of protected category.
● Internal Journal Rongchang People started.
● Rongchang was awarded as Advanced Private Enterprise of Shandong Province by Shandong Provincial Party Committee and Shandong Provincial People’s Government.
● Rongchang developed Gangtai Series Anti-hemorrhoids Ointment and Anti-hemorrhoids Suppository, which were included in the national level traditional Chinese medicine of confidential category.
● Rongchang was awarded as Hi-tech Enterprise of Shandong Province by Science and Technology Committee of Shandong Province.
● Rongchang was awarded as Excellent Technological Private Enterprise of Shandong Province by Science and Technology Committee of Shandong Province.
● Rongchang established RemeGen, Ltd. jointly with a famous Chinese scholar team in America and began to develop the new gene-based antitumor drug Vascular Endothelial Growth Inhibitor (Endu). The new project was included in the Key Projects of Shandong Provincial Torch Program in 1999 and 2000, and it was recognized as the key project in the pharmaceutical industry in the 1999 Technology Development Plan of Shandong Province.
● Rongchang gained the GMP certificate issued by CFDA.
● Rongchang invested 43 million Yuan and built the Bioengineering Laboratory of advanced level in China.
● Endu antitumor drug was included in the National 863 Program.
● Rongchang was reorganized as a limited liability company.
● Endu antitumor drug was approved by CFDA to enter into clinical trials (phase I) as a Class I new biological drug.
● Beijing Rongchang Medical Research Institute Co., Ltd. was registered and was recognized as a Hi-Tech enterprise by Beijing Science and Technology Committee.
● Anti-hemorrhoids patch, ointment and suppository products were included in the OTC drug category.
● Bisacodyl Suppository was awarded the New Drug Certificate by CFDA.
● Former President, General Secretary of the CPC central committee, and Chairman of Central Military Commission Hu Jintao visited the company.
● Endu antitumor drug gained the certificate of National Class I Class New Biologics and was approved to enter into market.
● The equity of Maidejin Biopharmaceutical Co., Ltd. was transferred to Simcere Pharmaceutical Group and the company name was changed to Shandong Xiansheng-Maidejin Biological Pharmaceutical Co., Ltd.
● Rongchang established RemeGen, Ltd. jointly with the famous Chinese Professor Fang Jianmin, dedicated to the original formulation of innovative biological drugs of proprietary intellectual property rights.
●Rongchang acquired the former Lutai-Huanzhong Pharmaceutical Co., Ltd. and changed its name to Rongchang Pharmaceuticals (Zibo), Ltd.
● On January 9, Rongchang, Tongji University and the Management Commission of Yantai Development Zone jointly signed an agreement in Beijing to build the Joint Platform and Development Base for New Biologic Drugs.
● “Tai’ai” was approved to enter the phase of clinical research by the China Food and Drug Administration.
● Tongji University and Yantai People’s Government jointly signed the University-Enterprise Strategic Cooperation Agreement. As part of the agreement, Tongji University, Managing Committee of Yantai Development Zone, and Remegen, Ltd. signed the “Agreement about Setting up Tongji University Yantai Academy and Joint Establishment of International Cooperative Biotechnology Company”.
● Tongji University set up “Tongji University Yantai Academy” in Rongchang Biopharmaceutical Park.
● On March 18, Rongchang moved to the Biopharmaceutical Park in Yantai Economic and Technological Development Zone.
● In September, the ADC new anti-tumor drug RC48 developed by RemeGen, Ltd. was approved to enter the phase of clinical research by China Food and Drug Administration. ADC is a new generation anti-tumor drug and RC48 is the first ADC drug in China that has been approved to enter the phase of clinical trial for human subject.